The Diagnostic Usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 δ in Follicular Thyroid Carcinoma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Follicular thyroid carcinoma (FTC) is the second most common thyroid malignancy and its differential diagnosis includes follicular adenoma (FA) and adenomatous goiter (AG). Several ancillary markers have been suggested to aid in the diagnosis of FTC, but the successful use of these methods still needs to be validated. Methods: In the present study, we verified the immunoexpression of HMGA2, CEACAM6, survivin, and SFN/14-3-3 δ in lesions including 41 AGs, 72 FAs, and 79 FTCs. We evaluated their diagnostic usefulness, combined with galectin 3, Hector Battifora mesothelial 1 (HBME1), cytokeratin 19, and cyclin D1, in diagnosing FTC. Results: The expressions of HBME1 (65.8%) and HMGA2 (55.7%) were significantly higher in FTCs than in FAs and AGs (p<.001 and p=.005, respectively). HBME1 was the only marker that was more frequently expressed in FTCs than in FAs (p=.021) and it was more frequently expressed in follicular neoplasms than in AGs (p<.001). Among the novel markers, the combination of HMGA2 and HBME1 showed the highest sensitivity (72.2%) and specificity (76.1%) for diagnosing FTC. CEACAM6, survivin, and SFN/14-3-3 δ were barely expressed in most cases. Conclusions: Our present results show that only HMGA2 can be beneficial in differentiating FTC using the novel markers.
Abstract
Background: Follicular thyroid carcinoma (FTC) is the second most common thyroid malignancy and its differential diagnosis includes follicular adenoma (FA) and adenomatous goiter (AG). Several ancillary markers have been suggested to aid in the diagnosis of FTC, but the successful use of these methods still needs to be validated. Methods: In the present study, we verified the immunoexpression of HMGA2, CEACAM6, survivin, and SFN/14-3-3 δ in lesions including 41 AGs, 72 FAs, and 79 FTCs. We evaluated their diagnostic usefulness, combined with galectin 3, Hector Battifora mesothelial 1 (HBME1), cytokeratin 19, and cyclin D1, in diagnosing FTC. Results: The expressions of HBME1 (65.8%) and HMGA2 (55.7%) were significantly higher in FTCs than in FAs and AGs (p<.001 and p=.005, respectively). HBME1 was the only marker that was more frequently expressed in FTCs than in FAs (p=.021) and it was more frequently expressed in follicular neoplasms than in AGs (p<.001). Among the novel markers, the combination of HMGA2 and HBME1 showed the highest sensitivity (72.2%) and specificity (76.1%) for diagnosing FTC. CEACAM6, survivin, and SFN/14-3-3 δ were barely expressed in most cases. Conclusions: Our present results show that only HMGA2 can be beneficial in differentiating FTC using the novel markers.
참고문헌 (24)
- Kapur U, "Follicular neoplasm of the thyroid: vanishing cytologic diagnosis?", Diagn Cytopathol, 35, pp.525~528 (2007)
- Wiseman SM, "Hemithyroidectomy : the optimal initial surgical approach for individuals undergoing surgery for a cytological diagnosis of follicular neoplasm", Ann Surg Oncol, 13, pp.425~432 (2006)
- McHenry CR, "Follicular adenoma and carcinoma of the thyroid gland", Oncologist, 16, pp.585~593 (2011)
- LiVolsi VA, "Follicular-patterned tumors of the thyroid: the battle of benign vs. malignant vs. so-called uncertain", Endocr Pathol, 22, pp.184~189 (2011)
- Sobrinho-Simões M, "Follicular thyroid carcinoma", Mod Pathol, 24(Suppl 2), pp.S10~S18 (2011)
- Mazzaferri EL, "Management of a solitary thyroid nodule", N Engl J Med, 328, pp.553~559 (1993)
- Baloch ZW, "Our approach to follicular-patterned lesions of the thyroid", J Clin Pathol, 60, pp.244~250 (2007)
- Prasad NB, "Three-gene molecular diagnostic model for thyroid cancer", Thyroid, 22, pp.275~284 (2012)
- Cerutti JM, "A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression", J Clin Invest, 113, pp.1234~1242 (2004)
- Cerutti JM, "Diagnosis of suspicious thyroid nodules using four protein biomarkers", Clin Cancer Res, 12(11 Pt 1), pp.3311~3318 (2006)
- Haghpanah V, "Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma", Appl Immunohistochem Mol Morphol, 14, pp.422~425 (2006)
- Belge G, "Upregulation of HMGA2 in thyroid carcinomas : a novel molecular marker to distinguish between benign and malignant follicular neoplasias", Genes Chromosomes Cancer, 47, pp.56~63 (2008)
- Chiappetta G, "HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias", Eur J Cancer, 44, pp.1015~1021 (2008)
- Prasad NB, "Identification of genes differentially expressed in benign versus malignant thyroid tumors", Clin Cancer Res, 14, pp.3327~3337 (2008)
- Paunovic I, "Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19and HBME-1 in differential diagnosis of thyroid tumors", APMIS, 120, pp.368~379 (2012)
- Bryson PC, "Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas", Arch Otolaryngol Head Neck Surg, 134, pp.581~586 (2008)
- Sigstad E, "The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors", Mod Pathol, 25, pp.537~547 (2012)
- de Matos PS, "Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy", Histopathology, 47, pp.391~401 (2005)
- Prasad ML, "Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors", Mod Pathol, 18, pp.48~57 (2005)
- Papale F, "Galectin-3 expression in thyroid fine needle cytology (t-FNAC) uncertain cases: validation of molecular markers and technology innovation", J Cell Physiol, 228, pp.968~974 (2013)
- Lal G, "Regulation of 14-3-3sigma expression in human thyroid carcinoma is epigenetically regulated by aberrant cytosine methylation", Cancer Lett, 267, pp.165~174 (2008)
- 김영아, "Detection of Survivin and COX-2 in Thyroid Carcinoma: Anaplastic Carcinoma Shows Overexpression of Nuclear Survivin and Low COX-2 Expression", Journal of Pathology and Translational Medicine, 46(1), pp.55~60 (2012), 대한병리학회
- 박영주, "Diagnostic Value of Galectin-3, HBME-1, Cytokeratin 19, HighMolecular Weight Cytokeratin, Cyclin D1 and p27kip1 in the DifferentialDiagnosis of Thyroid Nodules", Journal of Korean Medical Science, 22(4), pp.621~628 (2007), 대한의학회
- Saleh HA, "Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules", Diagn Pathol, 5, pp.9~ (2010)